Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 17, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 2,550,000 ordinary shares.
- Purchase Price: 1,270.50 pence per share.
- Treasury Holdings: 447,239,158 shares (representing 8.02% of total voting rights).
- Shares in Issue: 5,577,468,972 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the increase in the company's Treasury share holdings following the October 17, 2007 purchase. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the repurchase by multiplying 2,550,000 shares by 1,270.50 pence.
- Confirm the updated percentage of Treasury shares (8.02%) against the total voting rights.
- Note that the share count for voting rights calculations excludes the 447,239,158 Treasury shares.
- Recognize that this filing is a regulatory disclosure of a capital transaction and does not contain quarterly or annual financial results.